Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Bonus News
Abbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes. Article Published: 4/17/2026. 
Key Points
- Abbott Laboratories' stock price sell-off is overblown and unrealistic, providing an attractive opportunity in Q2.
- Institutions and analysts are accumulating this stock, indicating solid double-digit upside potential.
- Acquisitional woe hinders price action in April, but sets the market up for positive surprises and rebound later this year.
- Special Report: Elon Musk already made me a “wealthy man”
Abbott Laboratories' (NYSE: ABT) share price corrected by approximately 45% from peak to trough, bottoming in early Q2 2026 after reaching incredibly oversold levels. There are reasons for the sell-off, but the magnitude feels excessive given the fundamentals. Mixed results at the end of 2025 were compounded by cautious guidance and a controversial acquisition plan, which chilled investor enthusiasm. The next question is who is doing the selling and who is buying — and the data offers a clear picture. ABT Stock Is Well-Supported by Sell-Side Interests
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
MarketBeat's data shows meaningful support for Abbott among sell-side analysts. Of the 21 analysts tracked, there is strong conviction around a Moderate Buy rating, with an 81% Buy-side bias and a steady price-target trend. Some price-target cuts followed the Q4 results, but they tracked consensus, and sentiment has become more constructive since. Barclays analyst Matt Miksic raised his target in early April, reaffirming an Overweight rating and setting a $144 target — roughly 7.5% above the consensus. That consensus target sits about 40% above the security's critical support level. Institutions are also bullish, owning more than 75% of the float and accumulating shares for seven consecutive months. The only negative is that early Q2 trading shows some distribution, but that can reverse quickly. Data from 2026 shows bullish activity accelerating in Q1, reaching multiyear highs even as the stock price declined. If institutional buyers continue to take advantage of the post-earnings weakness, Abbott's downside floor is likely in the mid-$90s. Abbott Laboratories Market Hits Bottom in Q2The ABT stock price pulled back sharply after the Q1 report and could drift lower, but early action looks consistent with a bottoming process. The market gapped down at the open and then traded in a tight range near key support levels, suggesting buyers were active at these lows. Volume behavior also supports accumulation: it spiked alongside the sell-off, reaching intraday highs on a long-term basis. 
How long a rebound might take is uncertain, but technical indicators look favorable. The stochastic oscillator shows deeply oversold readings while the MACD divergence suggests bears are losing momentum and bulls are starting to take control. A clear catalyst could accelerate that turn — one candidate is visible progress integrating Exact Sciences, maker of Cologuard and Abbott’s pathway into high-growth oncology diagnostics. The main risk is that the stock lingers near current lows for several quarters, but even that scenario presents buying opportunities. Investors can use support levels as entry points to build positions over time. Abbott Laboratories Falls on Strong QuarterAbbott didn't report a bad quarter, but it did confirm a near-term drag from the acquisition. Still, revenue grew 7.8% year over year, with comparable growth of 3.7%. Foreign exchange provided a sizable tailwind, contributing roughly 400 basis points to revenue; U.S. sales rose about 2.5%, while international sales increased more than 4.5%. By segment, Nutrition was weakest, down 7.7% due to volume and pricing pressures, while other segments posted growth. Diagnostics grew 2.5% but should accelerate with Exact Sciences in the mix. Established Pharmaceuticals and MedTech led the way, up 9% and 8.1%, respectively, underscoring the company’s diversified mix. Margin details were less favorable, but they don't justify a near-50% share-price decline. Adjusted earnings were essentially in line with expectations, despite roughly 145 basis points of top-line strength. The key takeaway: Abbott's earnings and cash flow support a strong balance sheet and ongoing shareholder returns, and the outlook is constructive. Management Guides In-Line With ExpectationsLooking forward, management expects sequential revenue acceleration and margin recovery, forecasting 7% comparable growth at the midpoint and $5.48 in annual adjusted EPS — a penny above consensus. Given Abbott's track record with acquisitions and integrations, execution could drive upside to these projections. In the meantime, Abbott’s dividend and buyback program are likely to continue. The dividend yields a historically high ~2.5% at mid-April lows and comes with an impressive pedigree: ABT is both a Dividend Aristocrat and a Dividend King, having raised its payout for over 50 consecutive years. |
Post a Comment
Post a Comment